Diana Canto-Sims, OD, owner of Buena Vista Optical, discusses how Meta's donation of free AI glasses to blind veterans could close longstanding access gaps in low vision care—and where voice-command wearables fit alongside traditional rehabilitation tools.
Piotr Woźniak, MD, PhD, shares real-world evidence on Artelac Complete in dry eye disease from EuDEC 2026 in Milan, Italy, including improvements in tear break-up time and Schirmer scores, perioperative and contact lens use patterns, and high eye care practitioner satisfaction.
Their conversation covers a holistic, cross-specialty approach to ocular surface disease and the unmet need driving a new model of dry eye care in Ireland.
New aflibercept 8 mg label expands dosing from every 4 to 20 weeks, boosting flexibility, insurance support, and outcomes in tough retinal cases.
High-dose aflibercept 8 mg shows faster fluid drying and longer dosing intervals in AMD, DME and RVO, cutting injections without vision loss.
For Jay S. Duker, MD, and Ramiro Ribeiro, MD, PhD, paths that began in clinical and academic medicine became the foundation for a different kind of work—leading drug development from the inside.
Douglas D. Koch, MD, and Karolinne Maia Rocha, MD, PhD, discuss the optics behind enhanced monofocal lenses, patient selection, and how to set expectations.
SOL-1 data show OTX-TKI extends rescue-free control in treatment-naive wet AMD, shaping AI-driven trial design and longer-interval care.
New data show 8 mg aflibercept dries retinal fluid faster and lasts longer, enabling 12–16 week dosing in AMD, DME, and RVO.
Learn why newer anti‑VEGF options extend treatment for wet AMD, DME and RVO, signaling a shift from VEGF-only to multitarget therapy.
Host Deborah Ristvedt, DO, welcomes Vance Thompson, MD, to discuss how prioritizing people has shaped the culture and growth of Vance Thompson Vision.
In the latest episode of The Retina TL;DR with Dr. Weng, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr. Eichenbaum about the cell and gene therapy pipeline ahead, what sustains a career in retina, and why lifting others up is just what you do.
Meeting founder and co-chair Arshad M. Khanani, MD, MA, FASRS, shares what attendees can expect during this year's program, opening the evening of June 12 and running through June 13 in Las Vegas, Nevada.
Experts weigh vision-first goals in retinal disease, debating dry OCT vs stable fluid, longer anti‑VEGF intervals, and next‑gen durable therapies.
Experts discuss balancing vision, dry retina goals, fluid tolerance, and longer-lasting anti-VEGF options to cut injection burden.
NYU Langone’s Jordan Mandell, MD, and Ariana Levin, MD, sit down with UCLA’s Anne Coleman, MD, to discuss her recent study on cardiovascular risk scores and their association with glaucoma, AMD, and other ocular diseases.
Andrew G. Lee, MD, and Drew Carey, MD, discuss recurrence of papilledema after discontinuation of GLP-1 receptor agonists and the implications for monitoring patients with idiopathic intracranial hypertension.
In this episode, “Diagnostic Imaging in Retinal Vascular Disease Management,” the panelists explore how recent innovations in multimodal imaging are transforming the diagnosis and management of retinal vascular diseases, including AMD, diabetic macular edema (DME), diabetic retinopathy (DR), and retinal vein occlusion (RVO). The expert faculty discuss the growing role of optical coherence tomography (OCT) as the foundational imaging modality in retina clinics and how additional technologies such as fundus autofluorescence, OCT angiography (OCTA), and ultra-widefield imaging are expanding clinicians’ ability to detect and monitor disease activity.
Welcome back to another Ophthalmology Times series. In this episode titled, “Advancing Care Across Retinal Vascular Diseases,” the expert faculty discussed the evolving management of retinal vascular diseases, including age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR), and retinal vein occlusion (RVO). The panel reviewed the significant prevalence and treatment burden associated with these chronic retinal conditions, emphasizing how frequently these diseases are encountered in clinical retina practice and the challenges associated with maintaining long-term patient adherence to therapy.
Sharon Fekrat, MD, FACS, FASRS, reviews the science behind dopamine signaling in the retina and its potential role in the progression of age-related macular degeneration.
Dimitra Skondra, MD, PhD, FASRS, shares her perspective on the evolving treatment landscape for dry age-related macular degeneration and the key questions facing the field.
Carl D. Regillo, MD, FACS, reviews long-term efficacy and safety findings from the Port Delivery System clinical trial program.
Michael Singer, MD, discusses the role of steroids, biomarkers, and second-generation therapies in diabetic macular edema management.
In this interview from the 2026 Retina World Congress, Katherine Talcott, MD underscores that retinal vein occlusions (RVOs) should prompt retina specialists to look beyond the eye and ensure patients are connected to primary care and cardiology. She highlights the importance of systemic risk factor management and interdisciplinary coordination as essential components of comprehensive RVO care.
Ashkan Abbey, MD, reviews findings from the DAVIO2 and VERONA clinical trials for the bioerodible intravitreal insert.
Ultra-widefield pediatric retinal scans plus adaptable AI reveal hidden eye issues during routine visits, enabling comfortable, scalable screening and earlier specialist referrals.
Patricio G. Schlottmann, MD, examines why injection frequency drives treatment failure in wet AMD and the particular challenges facing patients in Latin America.
Caveolin‑1 is a membrane-associated protein expressed in many cell types that plays a key role in modulating inflammatory signaling.
Posture, operating room setup, and small workflow adjustments can reduce cumulative neck and back strain over time.
Jay Chhablani, MD, on multimodal imaging, OCT biomarkers, and the importance of early diagnosis as treatment options emerge
